Search

Your search keyword '"Romero Delgado F"' showing total 18 results
Start Over Author "Romero Delgado F"
18 results on '"Romero Delgado F"'

2. Encefalopatías y encefalitis durante la infección aguda por SARS-CoV2. Registro de la Sociedad Española de Neurología SEN COVID-19

Author

Abenza Abildúa, M.J., Atienza, S., Carvalho Monteiro, G., Erro Aguirre, M.E., Imaz Aguayo, L., Freire Álvarez, E., García-Azorín, D., Gil-Olarte Montesinos, I., Lara Lezama, L.B., Navarro Pérez, M.P., Pérez Sánchez, J.R., Romero Delgado, F., Serrano Serrano, B., Villarreal Vitorica, E., and Ezpeleta Echávarri, D.

Published
2021
Full Text
View/download PDF

7. Workload of on-call emergency room neurologists in a Spanish tertiary care centre. A one-year prospective study

Author

Rodríguez Cruz, P.M., Pérez Sánchez, J.R., Cuello, J.P., Sobrino García, P., Vicente Peracho, G., García Arratibel, A., Sánchez Guzmán, D., Bravo Quelle, N., Gutiérrez Ruano, B., Alarcón Morcillo, C., Cordido Henríquez, F., Romero Delgado, F., Muñoz González, A., Domínguez Rubio, R., Iglesias Mohedano, A.M., Martín Barriga, M.L., de la Casa Fages, B., Díaz Otero, F., Ezpeleta, D., García Pastor, A., and Gil Núñez, A.

Published
2014
Full Text
View/download PDF

8. Labor asistencial del equipo de guardia de neurología en un hospital terciario de Madrid: análisis prospectivo durante un año

Author

Rodríguez Cruz, P.M., Pérez Sánchez, J.R., Cuello, J.P., Sobrino García, P., Vicente Peracho, G., García Arratibel, A., Sánchez Guzmán, D., Bravo Quelle, N., Gutiérrez Ruano, B., Alarcón Morcillo, C., Cordido Henríquez, F., Romero Delgado, F., Muñoz González, A., Domínguez Rubio, R., Iglesias Mohedano, A.M., Martín Barriga, M.L., de la Casa Fages, B., Díaz Otero, F., Ezpeleta, D., García Pastor, A., and Gil Núñez, A.

Published
2013
Full Text
View/download PDF

10. Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study

Author

Cuello, J. P., primary, Martínez Ginés, M. L., additional, Kuhle, J., additional, García Domínguez, J. M., additional, Lozano Ros, A., additional, Romero Delgado, F., additional, Higueras, Y., additional, Meldaña Rivera, A., additional, Goicochea Briceño, H., additional, García‐Tizon Larroca, S., additional, De León-Luis, J., additional, Michalak, Z., additional, Barro, C., additional, Álvarez Lafuente, R., additional, Medina Heras, S., additional, Fernández Velasco, J. I., additional, Tejeda‐Velarde, A., additional, Domínguez‐Mozo, M. I., additional, Muriel, A., additional, de Andrés, C., additional, and Villar, L. M., additional

Published
2019
Full Text
View/download PDF

13. Labor asistencial del equipo de guardia de neurología en un hospital terciario de Madrid: análisis prospectivo durante un año

Author

Rodríguez Cruz, P.M., primary, Pérez Sánchez, J.R., additional, Cuello, J.P., additional, Sobrino García, P., additional, Vicente Peracho, G., additional, García Arratibel, A., additional, Sánchez Guzmán, D., additional, Bravo Quelle, N., additional, Gutiérrez Ruano, B., additional, Alarcón Morcillo, C., additional, Cordido Henríquez, F., additional, Romero Delgado, F., additional, Muñoz González, A., additional, Domínguez Rubio, R., additional, Iglesias Mohedano, A.M., additional, Martín Barriga, M.L., additional, de la Casa Fages, B., additional, Díaz Otero, F., additional, Ezpeleta, D., additional, García Pastor, A., additional, and Gil Núñez, A., additional

Published
2014
Full Text
View/download PDF

14. Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers

Author

De Andres, C, García, M I, Goicoechea, H, Martínez-Ginés, M L, García-Domínguez, J M, Martín, M L, Romero-Delgado, F, Benguría, A, Sanjurjo, M, and López-Fernández, L A

Abstract

Intravenous methylprednisolone (IVMP) is the gold standard treatment in acute relapses of multiple sclerosis. Knowing the response to IVMP in advance could facilitate earlier selection of patients for subsequent courses of therapy. However, molecular mechanisms and changes in gene expression induced by methylprednisolone remain unknown. The aim of the study was to identify in vivo differentially expressed genes in relapsing–remitting multiple sclerosis patients after 3–6 days of treatment with IVMP. For this purpose, whole-genome transcription profiling of CD4+ T lymphocytes was performed before and after treatment with IVMP in 8 relapsing–remitting multiple sclerosis patients during relapse using Human GE 4x44K v2 microarrays. Differentially expressed genes were identified using a paired t test on GeneSpring v13.0 software. A P-value <0.001 and a twofold change were considered significant. Microarray data were confirmed using real-time PCR. Microarray revealed changes in gene expression: four genes were downregulated (B3GNT3, ZNF683, IFNG and TNF) and seven upregulated (DEFA4, CTSG, DEFA8P, AZU1, MPO, ELANE and PRTN3). Pathway analysis revealed the transforming growth factor-β signaling pathway to be affected. Comparison with previously published data on in vitro methylprednisolone-regulated genes showed that SMAD7, TNF and CHI3L1 were also downregulated in vivo in relapsing–remitting multiple sclerosis patients. In summary, we performed the first in vivo transcriptome analysis in CD4+ T lymphocytes before and after the treatment with IVMP in patients with multiple sclerosis. Identification of differentially expressed genes in patients receiving IVMP could improve our understanding of the molecular mechanisms underlying the therapeutic effects of IVMP and highlight potential biomarkers of the response to IVMP.

Published
2018
Full Text
View/download PDF

15. Encefalopatías y encefalitis durante la infección aguda por SARS-CoV2. Registro SEN COVID-19

Author

Abenza Abildúa, M.J., Atienza, S., Carvalho Monteiro, G., Erro Aguirre, M.E., Imaz Aguayo, L., Freire Álvarez, E., García-Azorín, D., Gil-Olarte Montesinos, I., Binela Lara Lezama, L., Navarro Pérez, M.P., Pérez Sánchez, J.R., Romero Delgado, F., Serrano Serrano, B., Villarreal Vitorica, E., and Ezpeleta Echávarri, D.

Abstract

Desde el inicio de la pandemia por el virus SARS-CoV2 la Sociedad Española de Neurología (SEN) creó un registro de afectación neurológica para informar al neurólogo clínico. Las encefalopatías y encefalitis fueron una de las complicaciones más descritas. Analizamos las características de las mismas.

Published
2021
Full Text
View/download PDF

17. Impact of fampridine on quality of life: clinical benefit in real-world practice.

Author

Marzal-Alfaro MB, Martín Barbero ML, García Domínguez J, Romero-Delgado F, Martínez Ginés ML, Herranz A, and Sanjurjo-Sáez M

Abstract

Objectives: To assess the effectiveness and tolerability of fampridine in patients with multiple sclerosis (MS) in real clinical practice and to analyse adherence to treatment and general satisfaction of patients in terms of quality of life (QOL)., Methods: Patients who started treatment with fampridine from May 2014 to October 2014 were included. Primary and secondary outcomes were Timed 25-Foot Walk (T25FW) and MS Walking Scale-12 (MSWS-12) respectively, measured at baseline and 2 weeks, 3 and 6 months. Adherence was measured by the Morisky-Green questionnaire, patient satisfaction with a visual analogue scale (VAS) and QOL with improvement in mobility, self-care, daily activities, pain/discomfort or anxiety/depression., Results: 30 patients (46.7% women) of mean age 39 years, mean MS duration 13.7 years, mean Expanded Disability Status Scale score 5.8, 57% with relapsing-remitting MS were included. 22 patients (73%) continued to take treatment throughout the study period. Two weeks after treatment initiation all measures improved significantly from baseline (T25FW: -7.5 s, p<0.05; MSWS-12: -36.7, p<0.05). At 6 months, walking speed and self-perceived walking ability were significantly improved (T25FW: -3.8 s, p<0.05; MSWS-12: -30.0, p<0.05). Adverse events were reported by 30% of patients. Seizures were registered in one patient. 70% of patients were adherent with treatment. Median (IQR) general satisfaction VAS score was 8 (7-9). Patients reported an improvement in mobility (70%), anxiety/depression (33.3%), self-care (23.3%), daily activities (23.3%) and pain/discomfort (3.3%)., Conclusions: Fampridine is effective and safe in patients with MS in real clinical practice up to 6 months. Adherence to treatment was suboptimal but patients' general satisfaction was high and fampridine improved several items of QOL., Competing Interests: Competing interests: None declared.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results